Urothelial Carcinoma Treatment Global Market Report 2024

The global urothelial carcinoma treatment market has grown rapidly in recent years. It will grow from $2.41 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to rising prevalence of urothelial carcinoma, growing awareness of urothelial carcinoma, increasing access to healthcare, rising disposable incomes.

The global urothelial carcinoma treatment market is expected to see rapid growth in the next few years. It will grow to $5.33 billion in 2028 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to aging population, demand for personalized medicine, rising government support for urothelial carcinoma research and treatment, growing investments on urothelial carcinoma treatment. Major trends in the forecast period include biomarker-driven therapies, neoadjuvant and adjuvant approaches, liquid biopsies, minimally invasive surgeries, chemotherapy development, digital health technologies.

The surge in bladder cancer cases is anticipated to be a significant driver for the expansion of the urothelial carcinoma treatment market in the foreseeable future. Bladder cancer is a prevalent form of cancer that primarily affects the cells lining the urinary bladder, necessitating a variety of treatment options sought by patients and healthcare providers alike. In-depth research into bladder cancer informs the development of targeted therapies and provides valuable insights into urothelial carcinoma, fostering cross-disciplinary approaches that promise enhanced treatment outcomes. For example, in January 2022, data from the American Cancer Society Inc. revealed that the estimated cases of urinary bladder cancer in the United States reached 83,730 in 2021, marking a 2.8% increase from the 81,400 cases reported in 2020. This upward trend in bladder cancer cases is poised to drive the urothelial carcinoma treatment market.

The growing demand for chemotherapy is anticipated to be a significant driver for the growth of the urothelial carcinoma treatment market in the foreseeable future. Chemotherapy is a medical treatment that employs drugs to target and eradicate rapidly dividing cells within the body, commonly employed in cancer treatment. Chemotherapy's pivotal role stems from its effectiveness in managing various stages of the disease, making it an integral approach in urothelial carcinoma treatment. For instance, as of June 2023, Mesothelioma.com, a medical information provider based in the United States, reports that approximately 25% of cancer patients in the US receive chemotherapy each year. Hence, the increasing demand for chemotherapy is set to propel the urothelial carcinoma treatment market.

The substantial investment costs associated with urothelial carcinoma therapeutics are acting as a deterrent to the growth of the urothelial carcinoma treatment market. The elevated costs of pharmaceuticals and treatment regimens may discourage individuals from seeking treatment and could lead to dissatisfaction with the treatment outcomes. For instance, the high price tags of immune checkpoint inhibitors such as nivolumab/ipilimumab and atezolizumab pose limitations to their cost-effectiveness. These drugs are utilized in urothelial carcinoma treatment, and their high costs can render effective treatment options financially out of reach for many. Consequently, the high investment costs for urothelial carcinoma therapeutics are hindering the market.

The prominent companies operating in the urothelial carcinoma treatment market are actively dedicated to introducing innovative products to enhance their competitive positions and meet the changing needs of their customers. For example, in March 2023, Nonacus Limited, a UK-based medical product manufacturer, unveiled GALEAS Bladder, a cutting-edge diagnostic test designed for the non-invasive detection of bladder cancer. GALEAS Bladder represents a significant advancement in bladder cancer diagnostics, offering a comprehensive molecular triage solution that seamlessly moves from sample collection to the final diagnostic report. It leverages a molecular biomarker with exceptional sensitivity to quickly and accurately identify bladder cancer, simplifying the diagnostic process and reducing the necessity for invasive procedures like cystoscopies. Developed in partnership with the University of Birmingham in the UK, GALEAS Bladder has undergone rigorous validation, involving over 600 patient samples from three distinct clinical cohorts in the UK. This extensive assessment underscores the remarkable performance of GALEAS Bladder, delivering high diagnostic accuracy (with a sensitivity exceeding 90% and specificity over 85%) and effectively catering to varying bladder cancer grades and stages.

In March 2021, ImmunityBio Inc., a US-based immunotherapy company specializing in bladder cancer treatment, underwent a merger with NantKwest Inc. for an undisclosed sum. This strategic merger positions ImmunityBio and NantKwest to offer significant novel treatment alternatives to patients by leveraging their respective leading platforms, expertise, and resources. The goal of this collaboration is to accelerate the advancement of their product pipeline. NantKwest Inc. is a clinical-stage immunotherapy company dedicated to the development of various immunotherapeutic solutions designed to address several cancers, including urothelial carcinoma.

Major players in the urothelial carcinoma treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., GlaxoSmithKline PLC, Astellas Pharma Inc., Agilent Technologies Inc., Eisai Co. Ltd., Incyte Corporation, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Seagen Inc., Lupin Limited, Genentech Inc., UroGen Pharma Inc., Acerta Pharma B.V., Asieris Pharmaceuticals Co. Ltd., Pacific Edge Limited, Protara Therapeutics Inc., Hamlet Pharma AB, CG Oncology Inc., AroCell AB, ImmunityBio Inc., IDL Biotech AB.

North America was the largest region in the urothelial carcinoma treatment market in 2023. The regions covered in urothelial carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urothelial carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categories of urothelial carcinoma treatment are non-invasive and invasive. Non-invasive treatment pertains to addressing early-stage bladder cancer that has not spread to the deeper layers of the bladder or surrounding tissues. This is achieved through techniques like transurethral resection of bladder tumors (TURBT), which entails the removal of cancerous tissue from the bladder lining, and intravesical therapies, where medications are directly delivered into the bladder to prevent recurrence. These treatments, encompassing immunotherapy, radiotherapy, and chemotherapy, are also employed to address various types of urinary system cancers, including bladder, urethral, ureteric, and renal pelvic cancers. These treatments serve a variety of end users, including hospitals, homecare services, specialty centers, and others.

This report provides urothelial carcinoma treatment market statistics, including urothelial carcinoma treatment industry global market size, regional shares, competitors with a urothelial carcinoma treatment market share, detailed urothelial carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the urothelial carcinoma treatment industry. This urothelial carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urothelial carcinoma treatment market consists of revenues earned by entities by providing transurethral resection (TURBT) surgery and external beam radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The urothelial carcinoma treatment market also includes sales of platinum-based chemotherapy drugs such as cisplatin or carboplatin and immune checkpoint inhibitor drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.